Sanofi’s CEO Paul Hudson disclosed that the company integrates artificial intelligence into its drug development pipeline decision-making processes. AI tools provide dispassionate recommendations at senior review panels, advising whether to advance compounds through clinical development phases. This approach aims to circumvent human biases and career investments, promoting objective progression assessments. Sanofi has used AI in discovery for about three years, accounting for roughly a third of early-stage drug candidate evaluations, reflecting increased reliance on AI to streamline pharmaceutical innovation.